Ben Tao

739 total citations
10 papers, 452 citations indexed

About

Ben Tao is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, Ben Tao has authored 10 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Molecular Biology and 3 papers in Pharmacology. Recurrent topics in Ben Tao's work include Pharmacology and Obesity Treatment (3 papers), Diabetes Treatment and Management (3 papers) and Drug Transport and Resistance Mechanisms (2 papers). Ben Tao is often cited by papers focused on Pharmacology and Obesity Treatment (3 papers), Diabetes Treatment and Management (3 papers) and Drug Transport and Resistance Mechanisms (2 papers). Ben Tao collaborates with scholars based in United States, Japan and Germany. Ben Tao's co-authors include Sanjeev Saksena, John H. Williams, Eric N. Prystowsky, Philip D. Henry, Antonio Pacifico, Koichi Miyazaki, Reinilde Heyrman, Lydie Hazan, As’ad E. Bhorat and Michael R. Jones and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Hypertension.

In The Last Decade

Ben Tao

10 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ben Tao United States 6 314 64 60 52 34 10 452
Ana Pastora Otero Spain 4 128 0.4× 56 0.9× 61 1.0× 91 1.8× 32 0.9× 5 370
Frangiskos I. Parthenakis Greece 10 226 0.7× 44 0.7× 23 0.4× 41 0.8× 64 1.9× 21 325
Millar Ja Australia 9 169 0.5× 62 1.0× 44 0.7× 60 1.2× 40 1.2× 20 359
Sona Haku Japan 13 182 0.6× 101 1.6× 20 0.3× 97 1.9× 66 1.9× 25 366
Pi-Kai Chang Taiwan 8 83 0.3× 82 1.3× 50 0.8× 57 1.1× 49 1.4× 26 327
Ali Yıldız Türkiye 12 189 0.6× 23 0.4× 96 1.6× 35 0.7× 82 2.4× 27 384
Xiang Ma China 10 112 0.4× 31 0.5× 71 1.2× 49 0.9× 66 1.9× 31 359
Haidar Maatouk Germany 7 324 1.0× 39 0.6× 48 0.8× 147 2.8× 40 1.2× 8 581
Eiry Edmunds United Kingdom 8 173 0.6× 71 1.1× 28 0.5× 35 0.7× 45 1.3× 16 313
Wojciech Sobiczewski Poland 11 233 0.7× 38 0.6× 13 0.2× 41 0.8× 50 1.5× 40 353

Countries citing papers authored by Ben Tao

Since Specialization
Citations

This map shows the geographic impact of Ben Tao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Tao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Tao more than expected).

Fields of papers citing papers by Ben Tao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Tao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Tao. The network helps show where Ben Tao may publish in the future.

Co-authorship network of co-authors of Ben Tao

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Tao. A scholar is included among the top collaborators of Ben Tao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Tao. Ben Tao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Tachibana, Masaya, Thomas Marbury, George Atiee, et al.. (2025). Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study. Clinical Pharmacology in Drug Development. 14(8). 631–641. 1 indexed citations
2.
Gounder, Mrinal M., Todd M. Bauer, Gary K. Schwartz, et al.. (2023). A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. Journal of Clinical Oncology. 41(9). 1714–1724. 56 indexed citations
3.
Ito, Takashi, Tharin Limsakun, Hamim Zahir, et al.. (2022). Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor. Clinical and Translational Science. 15(4). 967–980. 3 indexed citations
4.
5.
He, Ling, et al.. (2014). Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. Diabetes Research and Clinical Practice. 104(3). 401–409. 12 indexed citations
6.
He, Ling, et al.. (2013). The effects of colesevelam HCl on the single‐dose pharmacokinetics of glimepiride, extended‐release glipizide, and olmesartan medoxomil. The Journal of Clinical Pharmacology. 54(1). 61–69. 4 indexed citations
7.
8.
9.
Hinderling, Peter H., et al.. (2006). Systemic Availability of the Active Metabolite Hydroxy‐Fasudil After Administration of Fasudil to Different Sites of the Human Gastrointestinal Tract. The Journal of Clinical Pharmacology. 47(1). 19–25. 24 indexed citations
10.
Pacifico, Antonio, John H. Williams, Ben Tao, et al.. (1999). Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. New England Journal of Medicine. 340(24). 1855–1862. 269 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Pastora Otero Breakdown of academic impact, for papers by Frangiskos I. Parthenakis Breakdown of academic impact, for papers by Millar Ja Breakdown of academic impact, for papers by Sona Haku Breakdown of academic impact, for papers by Pi-Kai Chang Breakdown of academic impact, for papers by Ali Yıldız Breakdown of academic impact, for papers by Xiang Ma Breakdown of academic impact, for papers by Haidar Maatouk Breakdown of academic impact, for papers by Eiry Edmunds Breakdown of academic impact, for papers by Wojciech Sobiczewski
Rankless by CCL
2026